The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Fc Protein and Glycoengineered Antibodies Market (2nd Edition), 2016 - 2026

  • Lowest Price Guaranteed From USD 2,199

  • Published
    March 2016

  • Pages
    327

  • View Count
    1106

Example Insights

  1. Overall, we have identified nearly 70 products in marketed, clinical and preclinical stages of development; nearly 60% of the pipeline accounts for molecules in clinical development.
  2. The market is characterized by the presence of both small and big pharma players. Notable examples of small to mid-sized firms include (in alphabetical order) arGEN-X, Celldex Therapeutics, Clovis Oncology, Five Prime Therapeutics, Genmab, Immune Design, MorphoSys, TG Therapeutics and Zymeworks. The larger companies in the domain include Amgen, AstraZeneca/MedImmune, Boehringer Ingelheim, Roche/Genentech, Kyowa Hakko Kirin and Merck.
  3. Several firms have also developed their proprietary technologies for Fc optimization and glycoengineering monoclonal antibodies. Examples include (in alphabetical order) BioWa with its POTELLIGENT® technology, Glycart with its GlycoMab Technology, Glycotope with its GlycoExpress™, ProBioGen with its GlymaxX® technology and Xencor with its XmAb Fc technology.
  4. Encouraging clinical results and prospects in multiple disease areas have yielded an intense framework of collaborative and licensing activity in this field. In fact, between 2005 and February 2016, there have been over 80 collaborations in this space.
  5. With two approved drugs, the glycoengineered antibodies are likely to emerge as the forerunner in the short term (84% of the market share by 2021). Subsequently, the Fc protein engineered antibodies are likely to garner a higher proportion (55% by 2026); specifically, Atezolizumab (by Roche) and Durvalumab (by AstraZeneca/MedImmune) are expected to be blockbusters.
  6. The overall market is anticipated to grow aggressively at a healthy annual growth rate of over 40% between 2016 and 2026. In the longer term, we expect the market to continue to rise steadily with high adoption rates of marketed drugs and approval of new drugs and indications.

Overview

Developed through introduction of modifications in monoclonal antibodies (mAbs), antibody based therapeutics are gaining increased attention from both large and small pharmaceutical companies. The Y-arm of the antibody is known as Fab, comprising a constant and a variable domain from each light and heavy chain. The variable domain (Fv) within the Fab region is responsible for target specificity and binding affinity whereas the base of the antibody, known as the fragment crystallizable (Fc) region, is responsible for interaction with immune cells. Modifications made in the Fc region can alter its effector functions. The key changes made in the Fc domain to improve the effector functions include glycoengineering, protein engineering or isotype chimerism. This can result in improvement in the ADCC activity, CDC activity, ADCP activity and half-life of the molecule.

The concept of engineered antibodies is widely being used for development for biobetters/biosimilars, addressing the drawbacks of their ancestor drug candidates. Several players have developed and made available their proprietary technologies for production of such engineered antibodies. This has encouraged and opened an opportunity for a large amount of licensing activity in this domain, building a strong collaborative network of small and big pharmaceutical companies.

Currently, two drugs, namely Gazyva® and POTELIGEO® , are commercially available. A number of molecules are being tested primarily for oncological indications; in addition, a limited set of molecules are also being developed for non-oncological indications such as asthma, COPD, neuromyelitis optica, ulcerative colitis and hemolytic disease in the newborn. Such initiatives suggest that the overall market is likely to hold a strong potential in the coming years.

 

Scope of the Report

The “Fc Protein and Glycoengineered Antibodies Market (2nd Edition), 2016-2026” report was commissioned to examine the various aspects of engineering an antibody to develop novel drugs for addressing several oncology and non-oncological disorders. This market has steadily evolved over the last few years. The report examines several elements of developing these next generation antibodies, such as the technologies used for their production, site of engineering in an antibody and a robust landscape in the form of clinical / preclinical pipeline. For the purposes of this report, engineered antibodies are defined as antibodies that have been modified in their Fc region. The two types of modification considered include:

  • Fc Glycoengineering (referred to as ‘Glycoengineering’ in the report)
  • Fc Protein engineering

As pharmaceutical companies continue to initiate and expand their research programs in this area, one of the key objectives outlined for this report was to understand the future potential of the market. This was done by analyzing:

  • The Fc protein and glycoengineered antibody pipeline in terms of phase of development, type of therapy (monotherapy or combination therapy) and target indications.
  • Technologies established by various players for development of engineered antibody therapeutics including the key mechanism involved, licencing activity, advantages and the molecules being developed using the technology.
  • Partnerships that have taken place in the recent past covering technology licensing, product development and commercialization agreements, clinical trial collaborations, product license agreements, acquisitions and other relevant agreements.
  • Inherent threats to growth in the short and long term.
  • The likely adoption of the Fc protein and glycoengineered antibodies by understanding the competition posed by the current treatment plans and the expected growth rate over the coming few years.

The study provides a detailed market forecast and opportunity analysis for the short-mid term (2016-2021) and long term (2021-2026). The research, analysis and insights presented in this report include potential sales of the approved drugs and the ones in late stages of development (phase III). To add robustness to our model, we have provided three scenarios for our market forecast; these include the conservative, base and optimistic scenarios. Our opinions and insights, presented in this study were influenced by several discussions we conducted with experts in this area. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  provides an executive summary of the report. It offers a high level view on where the Fc protein and glycoengineering antibodies market is headed in the mid to long term.

Chapter 3  maps the historical evolution of monoclonal antibodies and provides a general introduction to the underlying concepts of antibody based therapeutics. This covers details about the structure of antibodies and techniques used to optimize/engineer them. In addition to this, we have also briefly discussed advantages of engineered antibodies over traditional therapeutic

Chapter 4  includes information on nearly 70 molecules that are approved and are being evaluated in different stages of development (both clinical and preclinical/discovery). In this chapter, we have identified the companies that are active in this market and conducted a detailed pipeline analysis including information on type of therapy (monotherapy/combination therapy), most commonly targeted indications and the phase of development.

Chapter 5  focuses on the glycoengineered antibodies market. It gives comprehensive profiles of the marketed, phase III and phase II drug candidates with a detailed understanding on the history of development, mechanism of action, clinical development status and key clinical trial results. Furthermore, we have provided a brief overview on the companies developing these molecules.

Chapter 6  provides information on the Fc protein engineered antibodies market. We have profiled phase II drug candidates with a detailed understanding on the history of development, mechanism of action, clinical development status and key clinical trial results. Furthermore, we have provided a brief overview on the companies developing these molecules.

Chapter 7  gives a comprehensive view on the market forecast measuring the opportunity in the short mid-term (2016-2021) and the long term (2021-2026). We have presented the key assumptions, forecast methodology and corresponding sales forecast output for different target indications. In addition, we have highlighted the relative contribution of the approved, phase III and phase II/III Fc protein and glycoengineered molecules individually.

Chapter 8  highlights the key technologies available for the production of engineered antibodies. We aim to review the advantages of each technology in detail and analyze the licensing activity in the recent past.

Chapter 9  features an elaborate discussion on the collaborations and partnerships that have been forged amongst players in this market. We have also discussed the various partnership models in existence and the most common forms of deals/agreements that have evolved over time.

Chapter 10  provides our analysis of the market under the SWOT framework. This section identifies key elements that are likely to influence future growth and/or impede the progress.

Chapter 11  summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 12  is a collection of interview transcripts of the discussions that were held with key stakeholders in this market.

Chapter 13  is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 14  is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Monoclonal Antibody
3.2.1. How Monoclonal Therapy Works?
3.2.2. Parts of a Monoclonal Antibody
3.2.3. Fc Region and Effector Functions
3.2.4. Types of Fc Receptors
3.2.5. Engineering of the Fc Region
3.2.5.1. Glycoengineering
3.2.5.2. Protein Engineering
3.2.5.3. Isotype Chimerism
3.3. Antibody Based Therapeutics
3.3.1. Approved Antibody Therapies: Distribution by Year of Approval
3.4. Advantages of Engineered Antibodies
 
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Glycoengineered Antibodies: Development Pipeline
4.2.1. Distribution by Phase of Development
4.2.2. Distribution by Type of Indication
4.2.3. Distribution by Type of Therapy
4.2.4. Leading Players of the Industry
4.3. Fc Protein Engineered Antibodies: Development Pipeline
4.3.1. Distribution by Phase of Development
4.3.2. Distribution by Type of Indication
4.3.3. Distribution by Type of Therapy
4.3.4. Distribution by Type of Effector Function
4.3.5. Leading Players of the Industry
 
5. GLYCOENGINEERED ANTIBODIES MARKET
5.1. Chapter Overview
5.2. Kyowa Hakko Kirin
5.2.1. Company Overview
5.2.2. Financial Performance
5.2.3. Product Profile: Mogamulizumab (POTELIGEO® /KW-0761)
5.2.3.1. Drug Specification
5.2.3.2. Mechanism of Action
5.2.3.3. History of Development
5.2.3.4. Current Status of Development
5.2.3.5. Clinical Studies
5.2.3.6. Key Clinical Trial Results
5.2.3.7. Dosage Regimen and Sales Strategies
 
5.2.4. Product Profile: Benralizumab (KHK4563/MEDI-563)
5.2.4.1. Drug Specification
5.2.4.2. Mechanism of Action
5.2.4.3. History of Development
5.2.4.4. Current Status of Development
5.2.4.5. Clinical Studies
5.2.4.6. Key Clinical Trial Results
 
5.2.5. Product Profile: KHK4083
5.2.5.1. Drug Specification
5.2.5.2. Current Status of Development
5.2.5.3. Clinical Studies
 
5.3. Roche
5.3.1. Company Overview
5.3.2. Financial Performance
5.3.3. Product Profile: Obinutuzumab (Gazyva®/GA101/RG7159)
5.3.3.1. Drug Specification
5.3.3.2. Mechanism of Action
5.3.3.3. History of Development
5.3.3.4. Current Status of Development
5.3.3.5. Clinical Studies
5.3.3.6. Key Clinical Trial Results
5.3.3.7. Prescribing Information and Dosing Regimen
 
5.4. TG Therapeutics
5.4.1. Company Overview
5.4.2. Financial Performance
5.4.3. Product Profile: Ublituximab/TG-1101/LFB-R603
5.4.3.1. Drug Specification
5.4.3.2. Mechanism of Action
5.4.3.3. History of Development
5.4.3.4. Current Status of Development
5.4.3.5. Clinical Studies
5.4.3.6. Key Clinical Trial Results
 
5.5. MedImmune/AstraZeneca
5.5.1. Company Overview
5.5.2. Financial Performance
5.5.3. Product Profile: MEDI-551
5.5.3.1. Drug Specification
5.5.3.2. Mechanism of Action
5.5.3.3. History of Development
5.5.3.4. Current Status of Development
5.5.3.5. Clinical Studies
5.5.3.6. Key Clinical Trial Results
 
5.6. LFB Biotechnologies
5.6.1. Company Overview
5.6.2. Financial Performance
5.6.3. Product Profile: Roledumab/LFB-R593
5.6.3.1. Drug Specification
5.6.3.2. Mechanism of Action
5.6.3.3. History of Development
5.6.3.4. Current Status of Development
5.6.3.5. Clinical Studies
 
5.7. Glycotope
5.7.1. Company Overview
5.7.2. Product Profile: PankoMab-GEX™ (GT-MAB 2.5-GEX™)
5.7.2.1. Drug Specification
5.7.2.2. Mechanism of Action
5.7.2.3. History of Development
5.7.2.4. Current Status of Development
5.7.2.5. Clinical Studies
5.7.2.6. Key Clinical Trial Results
5.7.3. Product Profile: CetuGEX™ (GT-MAB 5.2-GEX™)
5.7.3.1. Drug Specification
5.7.3.2. Mechanism of Action
5.7.3.3. History of Development
5.7.3.4. Current Status of Development
5.7.3.5. Clinical Studies
5.7.3.6. Key Clinical Trial Results
 
6. Fc ENGINEERED ANTIBODIES MARKET
6.1. Chapter Overview
6.2. Roche/Genentech
6.2.1. Company Overview
6.2.2. Product Profile: Atezolizumab (MPDL3280A/RG7446)
6.2.2.1. Drug Specification
6.2.2.2. Mechanism of Action
6.2.2.3. History of Development
6.2.2.4. Current Status of Development
6.2.2.5. Clinical Studies
6.2.2.6. Key Clinical Trial Results
 
6.3. Astra Zeneca/MedImmnune
6.3.1. Company Overview
6.3.2. Product Profile: Durvalumab (MEDI 4736)
6.3.2.1. Drug Specification
6.3.2.2. Mechanism of Action
6.3.2.3. History of Development
6.3.2.4. Current Status of Development
6.3.2.5. Clinical Studies
6.3.2.6. Key Clinical Trial Results
 
6.4. Mentrik Biotech
6.4.1. Company Overview
6.4.2. Drug Profile: Ocaratuzumab (AME-133V/ LY2469298)
6.4.2.1. Drug Specification
6.4.2.2. Mechanism of Action
6.4.2.3. History of Development
6.4.2.4. Current Status of Development
6.4.2.5. Key Clinical Trial Results
 
6.5. MacroGenics
6.5.1. Company Overview
6.5.2. Financial Performance
6.5.3. Drug Profile: Margetuximab (MGAH22)
6.5.3.1. Drug Specification
6.5.3.2. Mechanism of Action
6.5.3.3. History of Development
6.5.3.4. Current Status of Development
6.5.3.5. Clinical Studies
6.5.3.6. Key Clinical Trial Results
6.5.4. Drug Profile: Teplizumab (MGA031/HOKT3Γ1 (ALA-ALA))
6.5.4.1. Drug Specification
6.5.4.2. Mechanism of Action
6.5.4.3. History of Development
6.5.4.4. Current Status of Development
6.5.4.5. Clinical Studies
6.5.4.6. Key Clinical Trial Results
 
6.6. Janssen Biotech (Johnson and Johnson)
6.6.1. Company Overview
6.6.2. Financial Performance
6.6.3. Drug Profile: JNJ-56022473
6.6.3.1. Drug Specification
6.6.3.2. Mechanism of Action
6.6.3.3. History of Development
6.6.3.4. Current Status of Development
6.6.3.5. Clinical Studies
6.6.3.6. Key Clinical Trial Results
 
6.7. MorphoSys
6.7.1. Company Overview
6.7.2. Financial Performance
6.7.3. Product Profile: MOR208
6.7.3.1. Drug Specification
6.7.3.2. Mechanism of Action
6.7.3.3. History of Development
6.7.3.4. Current Status of Development
6.7.3.5. Clinical Studies
6.7.3.6. Key Clinical Trial Results
 
7. MARKET FORECAST AND OPPORTUNITY ANALYSIS
7.1. Chapter Overview
7.2. Scope and Limitations
7.3. Forecast Methodology
7.4. Overall Fc Protein and Glycoengineered Antibodies Market
7.5. Glycoengineered Antibodies Market Forecast
7.5.1. POTELIGEO® (Kyowa Hakko Kirin)
7.5.1.1. Target Patient Population
7.5.1.2. Sales Forecast
7.5.2. Gazyva® (Roche/Genentech)
7.5.2.1. Target Patient Population
7.5.2.2. Sales Forecast
7.5.3. Benralizumab (AstraZeneca)
7.5.3.1. Target Patient Population
7.5.3.2. Sales Forecast
7.5.4. Ublituximab (TG Therapeutics)
7.5.4.1. Target Patient Population
7.5.4.2. Sales Forecast
7.5.5. Roledumab (LFB Biotechnologies)
7.5.5.1. Target Patient Population
7.5.5.2. Sales Forecast
7.5.6. MEDI-551 (MedImmune)
7.5.6.1. Target Patient Population
7.5.6.2. Sales Forecast
 
7.6. Fc Protein Engineered Antibodies Market Forecast
7.6.1. Atezolizumab (Roche)
7.6.1.1. Target Patient Population
7.6.1.2. Sales Forecast
7.6.2. Durvalumab (MedImmune)
7.6.2.1. Target Patient Population
7.6.2.2. Sales Forecast
7.6.3. Ocaratuzumab (Mentrik Biotech)
7.6.3.1. Target Patient Population
7.6.3.2. Sales Forecast
7.6.4. Margetuximab (MacroGenics)
7.6.4.1. Target Patient Population
7.6.4.2. Sales Forecast
7.6.5. MOR208 (MorphoSys)
7.6.5.1. Target Patient Population
7.6.5.2. Sales Forecast
 
8. TECHNOLOGICAL PLATFORMS FOR DEVELOPING ENGINEERED ANTIBODIES
8.1. Chapter Overview
8.2. POTELLIGENT® (BioWa, Subsidiary of Kyowa Hakko Kirin)
8.2.1. Overview
8.2.2. The Technology
8.2.3. Discovery of POTELLIGENT® Technology
8.2.4. Advantages of POTELLIGENT® Technology
8.2.5. POTELLIGENT® CHOK1SV: A 2-in-1 Technology
8.2.6. Drugs Based on POTELLIGENT® Technology
8.2.7. Technology Licensees
8.2.8. Product Alliances
8.2.8.1. Amgen
8.2.8.2. Teva Pharmaceuticals
8.2.8.3. MedImmune
 
8.3. GlycoMab Technology (GlycArt)
8.3.1. Overview
8.3.2. The Technology
8.3.3. Advantages of GlycoMab Technology
8.3.4. Drugs Based on GlycoMab Technology
 
8.4. GlycoExpress™ (Glycotope)
8.4.1. Overview
8.4.2. The Technology
8.4.3. Advantages of GlycoExpress™ Technology
8.4.4. Drugs Based on GlycoExpress™ Technology
 
8.5. GlymaxX® Technology (ProBioGen)
8.5.1. Overview
8.5.2. The Technology
8.5.3. Advantages of GlymaxX® Technology
8.5.4. Drugs Based on GlymaxX® Technology
8.5.5. Technology Licensees
 
8.6. XmAb® Antibody Technology (Xencor)
8.6.1. Overview
8.6.2. The Technology
8.6.3. Drugs Based on XmAb® Antibody Technology
8.6.4. Technology Licensees
8.6.5. Product Alliances
8.6.5.1. Amgen
8.6.5.2. MorphoSys
 
8.7. Other Fc Engineering Technologies
8.7.1. EMABling® Technology (LFB)
8.7.2. BryoTechnology (Greenovation Biotech)
8.7.3. MAGE 1.5 (Eureka Therapeutics)
8.7.4. Sugar Engineered Antibody (Seattle Genetics)
8.7.5. Other Technologies
 
9. RECENT DEVELOPMENTS
9.1. Chapter Overview
9.2. Partnership Models/Agreements
9.3. Recent Collaborations
9.4. Recent Collaborations: Distribution by Month /Year
9.5. Recent Collaborations: Distribution by Type of Model for Therapeutic Applications
9.6. Recent Collaborations: Distribution by Type of Product
9.7. Recent Collaborations: Most Active Companies with Multiple Collaborations
 
10. SWOT ANALYSIS
10.1. Chapter Overview
10.2. Strengths
10.3. Weaknesses
10.4. Opportunities
10.5. Threats
 
11. CONCLUSION
11.1. A Healthy Pipeline with Several Molecules in Late Stages of Development
11.2. Engineered Antibodies: A Platform for Development of Biobetters
11.3. With Established Technologies, the Companies are Steadily Broadening Their Pipeline
11.4. Increasing Partnerships: An Attractive Opportunity for Several Pharma Players
11.5. The Overall Market Offers a Huge Potential for Growth
11.6. Concluding Remarks
 
12. INTERVIEW TRANSCRIPTS
 
13. APPENDIX 1: TABULATED DATA
 
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1  Monoclonal Antibodies Nomenclature: Based on Type of Origin
Figure 3.2  Monoclonal Antibody Therapy: Mechanism of Action
Figure 3.3  Structure of Antibody
Figure 3.4  Types of Fc Region Modification
Figure 3.5  Approved Antibody Therapies: Distribution by Year of Approval
Figure 4.1  Glycoengineered Antibodies Pipeline: Distribution by Phase of Development
Figure 4.2 Glycoengineered Antibodies Pipeline: Distribution by Type of Indication
Figure 4.3 Glycoengineered Antibodies Pipeline: Distribution by Type of Therapy
Figure 4.4  Glycoengineered Antibodies Pipeline: Leading Players
Figure 4.5  Fc Protein Engineered Antibodies Pipeline: Distribution by Phase of Development
Figure 4.6  Fc Protein Engineered Antibodies Pipeline: Distribution by Type of Indication
Figure 4.7  Fc Protein Engineered Antibodies Pipeline: Distribution by Type of Therapy
Figure 4.8  Fc Protein Engineered Antibodies Pipeline: Distribution by Type of Effector Function
Figure 4.9  Fc Protein Engineered Antibodies Pipeline: Leading Players
Figure 5.1  Kyowa Hakko Kirin: Annual Sales, 2011-2015 (JPY Million)
Figure 5.2  Mogamulizumab: History of Development
Figure 5.3  Benralizumab: History of Development
Figure 5.4  Roche: Annual Sales, 2011-2015 (CHF Billion)
Figure 5.5  Roche Annual Sales, 2015: Distribution by Business Segment (CHF Billion, %)
Figure 5.6  Obinutuzumab: Annual Sales, 2013-2015 (CHF Million)
Figure 5.7  Obinutuzumab: History of Development
Figure 5.8  Ublituximab: History of Development
Figure 5.9  AstraZeneca: Annual Sales, 2011-2015 (USD Million)
Figure 5.10  LFB Biotechnologies: Annual Sales, 2012-2014 (EUR Million)
Figure 6.1  Atezolizumab: History of Development
Figure 6.2  Durvalumab: History of Development
Figure 6.3  MacroGenics: Annual Sales 2011-2015 (USD Million)
Figure 6.4  Johnson and Johnson: Annual Sales 2011-2015 (USD Million)
Figure 6.5  MorphoSys: Annual Sales 2011-2015 (EUR Million)
Figure 7.1  Overall Fc Protein and Glycoengineered Antibodies Market (USD Million): 2016-2026 (Base Scenario)
Figure 7.2  Evolution of Fc Protein and Glycoengineered Antibodies Market: 2016, 2021 and 2026 (Base Scenario, USD Million)
Figure 7.3  Glycoengineered Antibodies Market (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.4  Glycoengineered Antibodies Market (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.5  Glycoengineered Antibodies Market, 2026: Distribution of Therapeutic Areas (USD Million, %)
Figure 7.6  POTELIGEO® Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.7  POTELIGEO® Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.8 Gazyva® Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.9  Gazyva® Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.10  Benralizumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.11  Benralizumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.12  Ublituximab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.13  Ublituximab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.14  Roledumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.15  Roledumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.16  MEDI-551 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.17  MEDI-551 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.18  Fc Protein Engineered Antibodies Market (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.19  Fc Protein Engineered Antibodies Market (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.20  Atezolizumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.21  Atezolizumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.22  Durvalumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.23  Durvalumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.24 Ocaratuzumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.25  Ocaratuzumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.26  Margetuximab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.27  Margetuximab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.28  MOR208 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.29  MOR-208 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 9.1 Recent Collaborations: Distribution by Year
Figure 9.2  Recent Collaborations: Distribution by Type of Model
Figure 9.3  Recent Collaborations: Distribution by Type of Product
Figure 9.4  Recent Collaborations: Distribution by Company
Figure 11.1  Fc Protein and Glycoengineered Antibodies Market: Top Players
Figure 11.2  Overall Fc Protein and Glycoengineered Antibodies Market Summary (USD Million): 2016, 2021, 2026

List of Tables

Table 3.1  Features of Engineered Fc Regions
Table 3.2  List of Approved Antibody Therapies
Table 4.1  Glycoengineered Antibodies: Marketed and Development Pipeline
Table 4.2  Fc Protein Engineered Antibodies: Development Pipeline
Table 5.1  Glycoengineered Antibodies: Profiled Drugs
Table 5.2  Mogamulizumab: Orphan Drug Designation
Table 5.3  Mogamulizumab: Current Status of Development
Table 5.4  Mogamulizumab: Clinical Trials
Table 5.5  Mogamulizumab: Clinical Trial Endpoints (Hematological Cancer)
Table 5.6  Mogamulizumab: Clinical Trial Endpoints (Solid Tumors)
Table 5.7  Benralizumab: Current Status of Development
Table 5.8  Benralizumab: Clinical Trials
Table 5.9  Benralizumab: Clinical Trial Endpoints (COPD)
Table 5.10 Benralizumab: Clinical Trial Endpoints (Asthma)
Table 5.11 KHK4083: Current Status of Development
Table 5.12 KHK4083: Clinical Trials
Table 5.13 Obinutuzumab: Current Status of Development
Table 5.14  Obinutuzumab: Industry Sponsored Clinical Trials
Table 5.15  Obinutuzumab: Non-Industry Sponsored Clinical Trials
Table 5.16  Obinutuzumab: Phase II and Above Clinical Trial Endpoints (CLL)
Table 5.17  Obinutuzumab: Phase I and I/II Clinical Trial Endpoints (CLL)
Table 5.18  Obinutuzumab: Clinical Trial Endpoints (NHL)
Table 5.19  Obinutuzumab: Clinical Trial Endpoints (DLBCL and/or FL)
Table 5.20  Obinutuzumab: Clinical Trial Endpoints (Non-Oncological Indications)
Table 5.21  Obinutuzumab: CLL11 Trial Results
Table 5.22  Gazyva®: Dosage Regimen
Table 5.23  Ublituximab: Current Status of Development
Table 5.24  Ublituximab: Clinical Trials
Table 5.25  Ublituximab: Clinical Trial Endpoints (CLL)
Table 5.26  Ublituximab: Clinical Trial Endpoints (B-Cell Malignancies)
Table 5.27  MEDI-551: Current Status of Development
Table 5.28  MEDI-551: Clinical Trials
Table 5.29  MEDI-551: Clinical Trial Endpoints (Oncological Indications)
Table 5.30  MEDI-551: Clinical Trial Endpoints (Non-Oncological Indications)
Table 5.31  Roledumab: Current Status of Development
Table 5.32  Roledumab: Clinical Trials
Table 5.33  PankoMab-GEX™: Current Status of Development
Table 5.34 PankoMab-GEX™: Clinical Trials
Table 5.35  PankoMab-GEX™: Clinical Trial Endpoints
Table 5.36  CetuGEX™: Current Status of Development
Table 5.37  CetuGEX™: Clinical Trials
Table 5.38  CetuGEX™: Clinical Trial Endpoints
Table 6.1  Fc engineered Antibodies: Profiled Drugs
Table 6.2  Atezolizumab: Current Status of Development
Table 6.3  Atezolizumab: Industry Sponsored Clinical Trials
Table 6.4  Atezolizumab: Non-Industry Sponsored Clinical Trials 
Table 6.5  Atezolizumab: Phase III Clinical Trial Endpoints (NSCLC)
Table 6.6  Atezolizumab: Phase III Clinical Trial Endpoints (Other Oncological Indications)
Table 6.7  Durvalumab: Current Status of Development
Table 6.8  Durvalumab: Industry Sponsored Clinical Trials
Table 6.9  Durvalumab: Non-Industry Sponsored Clinical Trials
Table 6.10  Durvalumab: Phase III Clinical Trial Endpoints (NSCLC)
Table 6.11 Durvalumab: Phase III Clinical Trial Endpoints (Other Oncological Indications)
Table 6.12 Ocaratuzumab: Current Status of Development
Table 6.13 Margetuximab: Current Status of Development
Table 6.14 Margetuximab: Industry/Non-Industry Clinical Trials
Table 6.15  Margetuximab: Clinical Trial Endpoints
Table 6.16  Teplizumab: Clinical Trials
Table 6.17  JNJ-56022473: Clinical Trials
Table 6.18  MOR208: Current Status of Development
Table 6.19  MOR208: Clinical Trials
Table 6.20  MOR208: Clinical Trial Endpoints
Table 7.1  Fc Protein and Glycoengineered Antibodies: Market Potential of Candidates
Table 7.2  Poteligio®: Target Patient Population
Table 7.4  Benralizumab: Target Patient Population
Table 7.5  Ublituximab: Target Patient Population
Table 7.6  Roledumab: Target Patient Population
Table 7.7  MEDI-551: Target Patient Population
Table 7.8  Atezolizumab: Target Patient Population
Table 7.9  Durvalumab: Target Patient Population
Table 7.10 Ocaratuzumab: Target Patient Population
Table 7.11 Margetuximab: Target Patient Population
Table 7.12  MOR208: Target Patient Population
Table 8.1  Technology Platforms for Development of Engineered Antibodies
Table 8.2  POTELLIGENT®: Drugs Candidates
Table 8.3  Drugs Based on POTELLIGENT® Technology: Latest Updates
Table 8.4  POTELLIGENT®: Technology Licensing Agreements
Table 8.5  Comparison of Kd for Rituximab and Obinutuzumab
Table 8.6  GlycoMab Technology: Drug Candidates
Table 8.7  GlycoExpress™: Glycosylation Parameters
Table 8.8  GlycoExpress™: Drug Candidates
Table 8.9  GlymaxX®: Drug Candidates
Table 8.10 Drugs Based on GlymaxX® Technology: Latest Updates
Table 8.11  GlymaxX®: Technology Licensing Agreements
Table 8.12  XmAb®: Drug Candidates
Table 8.13  Drugs Based on XmAb® Antibody Technology: Latest Updates
Table 8.14  XmAb®: Technology Licensing Agreements
Table 8.15  EMABling®: Drug Candidates
Table 9.1  Fc Protein and Glycoengineered Antibodies: Recent Collaborations (2005-2016)
Table 10.1  SWOT Analysis of Engineered Antibodies Market
Table 13.1  Approved Antibody Therapies: Distribution by Year of Approval
Table 13.2  Glycoengineered Antibodies Pipeline: Distribution by Phase of Development
Table 13.3  Glycoengineered Antibodies Pipeline: Distribution by Type of Indication
Table 13.4  Glycoengineered Antibodies Pipeline: Distribution by Type of Therapy
Table 13.5  Glycoengineered Antibodies Pipeline: Leading Players
Table 13.6  Fc Protein Engineered Antibodies Pipeline: Distribution by Phase of Development
Table 13.7  Fc Protein Engineered Antibodies Pipeline: Distribution by Type of Indication
Table 13.8  Fc Protein Engineered Antibodies Pipeline: Distribution by Type of Therapy
Table 13.9  Fc Protein Engineered Antibodies Pipeline: Distribution by Type of Effector Function
Table 13.10  Fc Protein Engineered Antibodies Pipeline: Leading Players
Table 13.11 Kyowa Hakko Kirin: Annual Sales, 2011-2015 (JPY Million)
Table 13.12 Roche: Annual Sales, 2011-2015 (CHF Billion)
Table 13.13  Roche: Sales Distribution by Business Segment, 2015 (CHF Billion, %)
Table 13.14  Obinutuzumab: Annual Sales, 2013-2015 (CHF Million)
Table 13.15  AstraZeneca: Annual Sales, 2011-2015 (USD Million)
Table 13.16  LFB Biotechnologies: Annual Sales, 2012-2014 (EUR Million)
Table 13.17  MacroGenics: Annual Sales, 2011-2015 (USD Million)
Table 13.18  Johnson and Johnson: Annual Sales, 2011-2015 (USD Million)
Table 13.19  MorphoSys: Annual Sales, 2011-2015 (EUR million)
Table 13.20  Overall Fc Protein and Glycoengineered Antibodies Market (USD Million): 2016-2026 (Base Scenario)
Table 13.21  Overall Fc Protein and Glycoengineered Antibodies Market (USD Million): 2016-2026 (Optimistic Scenario)
Table 13.22  Overall Fc Protein and Glycoengineered Antibodies Market (USD Million): 2016-2026 (Conservative Scenario)
Table 13.23  Evolution of Fc Protein and Glycoengineered Antibodies Market: 2016, 2021 and 2026 (Base Scenario, USD Million)
Table 13.24  Glycoengineered Antibodies Market (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 13.25  Glycoengineered Antibodies Market (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 13.26  Glycoengineered Antibodies Market (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 13.27  Glycoengineered Antibodies Market (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 13.28  Glycoengineered Antibodies Market (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 13.29  Glycoengineered Antibodies Market (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 13.30  Glycoengineered Antibodies Market, 2026: Share of Therapeutic Areas (USD Million, %)
Table 13.31  Poteligeo® Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 13.32  Poteligeo® Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 13.33  Poteligeo® Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 13.34  Poteligeo® Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 13.35  Poteligeo® Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 13.36  Poteligeo® Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 13.37  Gazyva® Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 13.38  Gazyva® Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 13.39  Gazyva® Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 13.40  Gazyva® Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 13.41  Gazyva® Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 13.42  Gazyva® Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 13.43  Benralizumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 13.44  Benralizumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 13.45  Benralizumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 13.46  Benralizumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 13.47  Benralizumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 13.48  Benralizumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 13.49  Ublituximab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 13.50  Ublituximab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 13.51  Ublituximab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 13.52  Ublituximab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 13.53  Ublituximab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 13.54  Ublituximab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 13.55  Roledumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 13.56  Roledumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 13.57  Roledumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 13.58  Roledumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 13.59  Roledumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 13.60  Roledumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 13.61  MEDI-551 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 13.62  MEDI-551 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 13.63  MEDI-551 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 13.64  MEDI-551 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 13.65  MEDI-551 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 13.66  MEDI-551 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 13.67  Fc Protein EngineeredAntibodies Market (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 13.68  Fc Protein EngineeredAntibodies Market (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 13.69  Fc Protein EngineeredAntibodies Market (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 13.70  Fc Protein EngineeredAntibodies Market (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 13.71  Fc Protein EngineeredAntibodies Market (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 13.72  Fc Protein EngineeredAntibodies Market (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 13.73  Atezolizumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 13.74  Atezolizumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 13.75  Atezolizumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 13.76  Atezolizumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 13.77  Atezolizumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 13.78  Atezolizumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 13.79  Durvalumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 13.80  Durvalumab Sales Forecast (USD Million), Long Term Forecast: 2016-2021 (Base Scenario)
Table 13.81  Durvalumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 13.82  Durvalumab Sales Forecast (USD Million), Long Term Forecast: 2016-2021 (Optimistic Scenario)
Table 13.83  Durvalumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 13.84  Durvalumab Sales Forecast (USD Million), Long Term Forecast: 2016-2021 (Conservative Scenario)
Table 13.85  Ocaratuzumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 13.86  Ocaratuzumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 13.87  Ocaratuzumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 13.88  Ocaratuzumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 13.89  Ocaratuzumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 13.90  Ocaratuzumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 13.91  Margetuximab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 13.92  Margetuximab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 13.93  Margetuximab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 13.94  Margetuximab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 13.95  Margetuximab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 13.96  Margetuximab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 13.97  MOR-208 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 13.98  MOR-208 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 13.99  MOR-208 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 13.100 MOR-208 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 13.101  MOR-208 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 13.102  MOR-208 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 13.103  Recent Collaborations: Distribution by Year
Table 13.104  Recent Collaborations: Distribution by Type of Model
Table 13.105  Recent Collaborations: Distribution by Type of Product
Table 13.106  Recent Collaborations: Distribution by Company
Table 13.107  Fc Protein and Glycoengineered Antibodies Market: Top Players
Table 13.108  Overall Fc Protein and Glycoengineered Antibodies Market Summary (USD Million): 2016, 2021, 2026

Listed Companies

The following companies and institutes have been mentioned in this report.

  1. AACR
  2. AbbVie
  3. ABN AMRO Capital
  4. Abramson Cancer Center of the University of Pennsylvania
  5. Advaxis
  6. Agensys
  7. Alexion Pharmaceuticals
  8. Amgen
  9. Applied Molecular Evolution
  10. Arana Therapeutics
  11. Archimedes Pharma
  12. arGEN-X
  13. AstraZeneca
  14. Avon Breast Cancer Foundation
  15. Bayer Healthcare
  16. Berlin-Chemie (Menarini Group)
  17. Biogen Idec
  18. BioMedinvest
  19. BioWa
  20. Boehringer Ingelheim
  21. Bristol-Myers Squibb
  22. Cambridge Antibody Technology
  23. Cancer Research Institute
  24. Cantargia
  25. Celgene
  26. Celldex Therapeutics
  27. Cellective Therapeutics
  28. Centocor Research and Development
  29. Chugai Pharmaceutical
  30. Clinical Cancer Research
  31. Columbia University Medical Center
  32. Committee for Medicinal Products for Human Use
  33. CSL Limited
  34. CTI BioPharma
  35. Cure Brain Cancer Foundation
  36. Daiichi Sankyo
  37. Dana-Farber Cancer Institute
  38. Deutsche Venture Capital
  39. Eisai
  40. Eli Lilly
  41. Eureka Therapeutics
  42. European Cancer Congress
  43. European Hematology Association
  44. Five Prime Therapeutics
  45. Fondazione Italiana Linfomi ONLUS
  46. Fountain BioPharma
  47. Fredrick Manufacturing Center
  48. GamaMabs Pharma
  49. Genentech
  50. Genitourinary Cancers Symposium of the American Society of Clinical Oncology
  51. Genzyme
  52. German Breast Group
  53. German CLL Study Group
  54. Gilde Investment Management
  55. GlaxoSmithKline
  56. Global Life Science Ventures
  57. GlycArt Biotechnology
  58. Glycode
  59. GlycoFi
  60. Glycotope Biotechnology
  61. Green Cross
  62. Greenovation Biotech
  63. GSK
  64. GTC Biotherapeutics
  65. Hoosier Cancer Research Network
  66. Human Genome Sciences
  67. Ildong Pharmaceutical
  68. ImmunoCellular Therapeutics
  69. Immunocore
  70. Incyte Corporation
  71. Inhibrx
  72. Institute of Cancer Research, United Kingdom
  73. Italian Network for Tumor Biotherapy Foundation
  74. Janssen Pharmaceuticals (Johnson & Johnson)
  75. Johannes Gutenberg University Mainz
  76. Juno Therapeutics
  77. Kairos Therapeutics
  78. KaloBios Pharmaceuticals
  79. King Faisal Specialist Hospital & Research Center
  80. Kolltan 
  81. Kyowa Hakko Kirin
  82. Kyowa Hakko Kogyo
  83. LFB Biotechnologies
  84. Lonza
  85. Ludwig Institute for Cancer Research
  86. M.D. Anderson Cancer Center
  87. MacroGenics
  88. MedImmune
  89. Memorial Sloan Kettering Cancer Center
  90. Menarini
  91. Mentrik Biotech
  92. Merck
  93. Merus
  94. Mirati Therapeutics
  95. MorphoSys
  96. Nantes University Hospital
  97. Naomi Berrie Diabetes Center
  98. National Cancer Institute
  99. National Institute of Allergy and Infectious Diseases
  100. NCIC Clinical Trials Group
  101. NEMOD Biotherapeutics
  102. Neovii Biotech
  103. National Institutes of Health
  104. NKT Therapeutics
  105. NorthWestern University
  106. Novartis
  107. Novo Nordisk
  108. OncoTherapy Science
  109. Ono Pharmaceutical
  110. Orpegen Pharma
  111. Otsuka Pharmaceutical
  112. Oxford BioTherapeutics
  113. Parexel
  114. Peregrine Pharmaceuticals
  115. Pfizer
  116. Pharmaceuticals and Medical Devices Agency
  117. Pharmacyclics
  118. PRA Health Sciences
  119. PrECOG
  120. ProBioGen
  121. ProStrakan
  122. Queen Mary University of London
  123. Quester Capital Management
  124. Raven Biotechnologies
  125. Regeneron
  126. Roche
  127. Sanofi
  128. Seattle Genetics
  129. Servier
  130. Sidney Kimmel Comprehensive Cancer Center
  131. Sorrento Therapeutics
  132. Spectrum Pharmaceuticals
  133. Swiss Federal Institute of Technology
  134. Synimmune
  135. Synthon
  136. Takeda Pharmaceuticals
  137. Teva Pharmaceuticals
  138. TG Therapeutics
  139. Tiziana Life Sciences 
  140. Tizona Therapeutics
  141. Tolerance Therapeutics
  142. UCB Pharma
  143. United Therapeutics
  144. University of Bern
  145. University of California, San Diego
  146. Ventana Medical Systems
  147. VentiRx Pharmaceuticals
  148. Xencor
  149. Zymeworks
     

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 2,199

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com